A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it
works during the course of painful crises. The overall hypothesis that we seek to test is
that increased platelet activation and the resultant inflammatory responses are important
contributors to the problems of sickle cell disease. Sickle cell disease has been referred to
both as a condition associated with increased risk of blood clots and increased inflammation.
A painful crisis represents the most common cli nical problem in sickle cell disease, but the
treatment of these crises remains inadequate.